Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022
19 Juli 2022 - 10:30PM
Nyxoah to Release Second Quarter and First
Half 2022 Financial Results on August 8, 2022
Mont-Saint-Guibert, Belgium – July 19, 2022,
10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq:
NYXH) (“Nyxoah” or the “Company”), a medical technology
company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today
announced that the Company will release financial results for the
second quarter and first half of 2022 on Monday, August 8, 2022,
after market close. Company management will host a conference call
to discuss financial results that day beginning at 10:30pm CET /
4:30pm ET.
Investors interested in listening to the
conference call may do so by registering for a unique personal PIN
at the following
link: https://register.vevent.com/register/BIfc3a52c9352e4e42958e9d816245b3b9.
A live and archived webcast of the event will be available on the
Company’s investor relations website
at https://investors.nyxoah.com/events.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea
(OSA). Nyxoah’s lead solution is the Genio® system, a
patient-centered, leadless and battery-free hypoglossal
neurostimulation therapy for OSA, the world’s most common sleep
disordered breathing condition that is associated with increased
mortality risk and cardiovascular comorbidities. Nyxoah is driven
by the vision that OSA patients should enjoy restful nights and
feel enabled to live their life to its fullest.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Nyxoah completed two successful IPOs: on Euronext Brussels in
September 2020 and NASDAQ in July 2021. Following the positive
outcomes of the BETTER SLEEP study, Nyxoah received CE mark
approval for the expansion of its therapeutic indications to
Complete Concentric Collapse (CCC) patients, currently
contraindicated in competitors’ therapy. Additionally, the Company
is currently conducting the DREAM IDE pivotal study for FDA and US
commercialization approval.
For more information, please
visit http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Contacts:NyxoahLoïc Moreau, Chief
Financial Officercorporate@nyxoah.com+32 473 33 19 80
Jeremy Feffer, VP IR and Corporate
Communicationsjeremy.feffer@nyxoah.com+1 917 749 1494
- ENGLISH_Q2 2022 Earnings Call Save-the-Date_FINAL
Nyxoah (EU:NYXH)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Nyxoah (EU:NYXH)
Historical Stock Chart
Von Apr 2023 bis Apr 2024